Acrivon Therapeutics Inc (ACRV) Stock Price, Quote & News

Company Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 207 8979

Website: acrivon.com

Address:

480 Arsenal Way, Suite 100, Watertown, United States

alphaonetrading Jul. 26 at 6:10 AM

$ACRV at 1.12/share, trading well below its DCF-derived value of $4.10, a 266% upside. With $164.8M in cash—nearly 4x its $42.95M market cap—and a runway to Q2 2027, ACRV is financially robust. Its pipeline, led by ACR-368 (Phase 2, Fast Track, approval ~2030) and ACR-2316 (Phase 1, ~2031), targets high-value oncology markets. Despite a conservative 5% success probability, positive Phase 2 data could drive significant revaluation. With 60.8% institutional ownership and moderate 4.58% short interest, ACRV offers a high-risk, high-reward opportunity for patient investors.

0 · Reply

Dani_G_German Jul. 25 at 6:56 PM

$ACRV One month charts are still intact, pushing upward for all three. $LRMR $ALUR

0 · Reply

lola269 Jul. 25 at 1:59 PM

$ACRV added

0 · Reply

Nikolabull Jul. 25 at 9:36 AM

$ACRV I found this paper potential My DD: Acrivon Therapeutics (ACRV): Market Cap 42.95 M USD, Shares Outstanding 38.35 M, Institutional Ownership 60.8 %, Short Interest 4.58 %, Cash Available 164.8 M USD, Burn Rate 19.5 M USD/qtr, Runway ≈ 8.5 qtrs (into Q2 2027), Products: ACR‑368 – registrational‑intent Phase 2 (Fast Track; expected approval ≈ 2030), ACR‑2316 – Phase 1 monotherapy (expected approval ≈ 2031), 1‑year Price Target: $11.56 (avg.) as of July 17, 2025 $TNXP very bullish, expecting fda approval

1 · Reply

Othoz Jul. 24 at 5:13 PM

$ACRV any news ?

1 · Reply

Filvul Jul. 24 at 1:59 PM

$IOVA $ACRV $AUTL $ATYR $CCCC

0 · Reply

lola269 Jul. 24 at 1:58 PM

Yayy coordinated short attack and what do we do in instances like these?? We buy like fucking degenerates Lfg!! $IOVA $ACRV $AUTL $ATYR $CCCC

0 · Reply

Dani_G_German Jul. 23 at 8:07 PM

$ACRV $2 next

0 · Reply

PreGigs Jul. 23 at 6:30 PM

$ACRV any up is a good up!

0 · Reply

lola269 Jul. 23 at 4:17 PM

$ACRV

0 · Reply

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Apr 25, 2025, 8:00 AM EDT - 3 months ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Apr 7, 2025, 4:05 PM EDT - 3 months ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Mar 27, 2025, 5:44 PM EDT - 4 months ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 19, 2025, 8:00 AM EDT - 4 months ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Dec 12, 2024, 3:25 PM EST - 8 months ago

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Oct 16, 2024, 4:00 PM EDT - 10 months ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 11, 2024, 8:00 AM EDT - 10 months ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Sep 18, 2024, 10:11 AM EDT - 11 months ago

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 14, 2024, 3:10 AM EDT - 11 months ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Jun 13, 2024, 2:00 PM EDT - 1 year ago

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

May 29, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 24, 2024, 7:16 PM EDT - 1 year ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 16, 2024, 8:01 PM EDT - 1 year ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 3, 2024, 3:07 AM EDT - 1 year ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 4:30 PM EST - 1 year ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Feb 27, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 12, 2024, 4:00 PM EST - 1 year ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 21, 2023, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 9, 2023, 8:01 AM EST - 1 year ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 19, 2023, 4:32 PM EDT - 2 years ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 5, 2023, 4:05 PM EDT - 2 years ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jun 22, 2023, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Mar 26, 2023, 9:53 AM EDT - 2 years ago

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Mar 6, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Nov 14, 2022, 10:16 PM EST - 2 years ago

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Nov 3, 2022, 7:52 AM EDT - 2 years ago

Acrivon Therapeutics sets IPO price range

Oct 19, 2022, 11:50 AM EDT - 3 years ago

Acrivon Therapeutics Begins U.S. IPO Rollout

alphaonetrading Jul. 26 at 6:10 AM

0 · Reply

Dani_G_German Jul. 25 at 6:56 PM

$ACRV One month charts are still intact, pushing upward for all three. $LRMR $ALUR

0 · Reply

lola269 Jul. 25 at 1:59 PM

$ACRV added

0 · Reply

Nikolabull Jul. 25 at 9:36 AM

1 · Reply

Othoz Jul. 24 at 5:13 PM

$ACRV any news ?

1 · Reply

Filvul Jul. 24 at 1:59 PM

$IOVA $ACRV $AUTL $ATYR $CCCC

0 · Reply

lola269 Jul. 24 at 1:58 PM

Yayy coordinated short attack and what do we do in instances like these?? We buy like fucking degenerates Lfg!! $IOVA $ACRV $AUTL $ATYR $CCCC

0 · Reply

Dani_G_German Jul. 23 at 8:07 PM

$ACRV $2 next

0 · Reply

PreGigs Jul. 23 at 6:30 PM

$ACRV any up is a good up!

0 · Reply

lola269 Jul. 23 at 4:17 PM

$ACRV

0 · Reply

Dani_G_German Jul. 23 at 2:21 PM

$ACRV

0 · Reply

lola269 Jul. 22 at 1:11 PM

$IOVA they will try to fuck us today They'll probably fail, stay strong mates! $ACRV getting there slowly and sensually $AUTL no move on good news! That's that biotech charm, don't get discouraged, it's heavily controlled , we are getting there. $ATYR last patient, open road till verdict. Got a nice dip too, added $CCCC finding support through a bull run is 10/10 experience, recommend Lfg!

1 · Reply

Dani_G_German Jul. 22 at 11:08 AM

$ACRV gotta get passed 1.42 once that happens $2 next to complete the cup

1 · Reply

lola269 Jul. 21 at 3:21 PM

$ACRV

0 · Reply

PreGigs Jul. 21 at 2:47 PM

$ACRV 5$ I'll take it please!

0 · Reply

Dani_G_German Jul. 21 at 2:45 PM

$ACRV

0 · Reply

lola269 Jul. 18 at 8:53 PM

$IOVA good people of this board once again we need to collectively chill ( and buy the dip) . The battle for 2$ was very hard by itself so don't sweat this that much. If we consider the enormous si we good from 2.40 to 2.20. Maybe some sold too for small profits. P.s. I see the Gremlins around the board that begun shit talking already - that's a bullish sign! $ACRV my posts worked!! Two whole persons popped up in the board!weeee $ATYR well..it's Friday and it's 6 so..lfg! $CCCC this keeps getting funnier $AUTL shorted and about to be bought again, we shall continue! Lfg!!

1 · Reply

PreGigs Jul. 18 at 1:54 PM

$ACRV is my bag finally going to move?

1 · Reply

Dani_G_German Jul. 17 at 6:50 PM

$ACRV is it finally gonna pop ??? Or retrace again?!

1 · Reply

lola269 Jul. 17 at 11:25 AM

$IOVA probably gonna try to stop it today mates if not or if unsuccessful then this will continue flying unapologetically,stay strong $ACRV need a couple o burley boys to keep me company here $CCCC C(ompletely) C(certified) C(ash) C(ow) $AUTL maybe picks up again today $ATYR it's not dropping and I want to buy

2 · Reply

lola269 Jul. 16 at 12:48 PM

$IOVA we did great yesterday,let's stay strong today too. Another block placed $ACRV still alone $CCCC C(ure) C(ancer) C(ash) C(oke) in that order $ATYR 6 by Friday $AUTL still good Lfg!

3 · Reply

lola269 Jul. 15 at 3:11 PM

Today is biotech shorting day Henceforth today is buy day Look at all of them..down on no news or good news Added today mates LFG! $IOVA $ACRV $AUTL $CCCC $ATYR

1 · Reply

Market Cap	44.84M
Revenue (ttm)	0.00
Net Income (ttm)	-80.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	332,200
Avg Vol	499,174
Day's Range	N/A - N/A
Shares Out	31.36M
Stochastic %K	74%
Beta	1.64
Analysts	Strong Sell
Price Target	$12.00